Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

30.02 +2.65 (+9.68%)
Streaming Delayed Price Updated: 12:54 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. ↗
A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects. 
Via Chartmill
News headline image
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for high Growth Investing Strategies? ↗
A fundamental and technical analysis of (NASDAQ:CPRX): Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for growth investors. Here's why. ↗
A fundamental analysis of (NASDAQ:CPRX): CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for growth investors. Here's why. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Why NASDAQ:CPRX qualifies as a high growth stock. ↗
A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects. 
Via Chartmill
News headline image
Unlocking the Growth Potential of NASDAQ:CPRX. ↗
A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
News headline image
Why Mark Minervini may look into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) ↗
A fundamental and technical analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing? 
Via Chartmill
News headline image
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday ↗
Via The Motley Fool
Topics Economy Government World Trade
News headline image
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). ↗
A fundamental analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing? 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is showing decent growth, but is still valued reasonably. ↗
CATALYST PHARMACEUTICALS INC could be undervalued. NASDAQ:CPRX is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
News headline image
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing? ↗
A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
News headline image
Exploring NASDAQ:CPRX's high growth characteristics. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why. Full fundamental and technical analysis of (NASDAQ:CPRX). 
Via Chartmill
News headline image
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? ↗
Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your... 
Via Benzinga
News headline image
For those who appreciate value investing, CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a compelling option with its solid fundamentals. ↗
Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
News headline image
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a CANSLIM stock. ↗
A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for Growth Investing Strategies? 
Via Chartmill
News headline image
Looking for growth without the hefty price tag? Consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). ↗
CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced... 
Via Chartmill
News headline image
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock? ↗
Based on a technical and fundamental analysis of NASDAQ:CPRX we are exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing? ↗
A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing? 
Via Chartmill
News headline image
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today ↗
The drugmaker confirmed there's a strong market for two of its treatments. 
Via The Motley Fool
News headline image
Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
CATALYST PHARMACEUTICALS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:CPRX showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Investors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced. ↗
Based on Fundamental Analysis it can be said that NASDAQ:CPRX is a growth stock which is not overvalued. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
The Company will Host a Conference Call and Webcast on February 27, 2025, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
Based on a technical and fundamental analysis of NASDAQ:CPRX we can say: CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
NASDAQ:CPRX: good value for what you're paying. ↗
Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
News headline image
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.